These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33109387)

  • 1. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
    Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
    Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients.
    Kandeel EZ; El Sayed G; Elsharkawy N; Eldin DN; Nassar HR; Ibrahiem D; Amin R; Hanafi M; Khalil M; Kamel A
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):541-547. PubMed ID: 29907544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fms-like tyrosine kinase 3 mutations in childhood acute leukemias and their association with prognosis.
    Karabacak BH; Erbey F; Bayram I; Yilmaz S; Acipayam C; Kilinç Y; Tanyeli A
    Asian Pac J Cancer Prev; 2010; 11(4):923-7. PubMed ID: 21133602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Loken MR; Gerbing RB; Ries RE; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Kahwash SB; McKenney A; Kolb EA; Gamis AS; Meshinchi S
    Clin Cancer Res; 2017 Jul; 23(14):3649-3656. PubMed ID: 28108543
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
    Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
    Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
    Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
    Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
    Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
    Santos FP; Jones D; Qiao W; Cortes JE; Ravandi F; Estey EE; Verma D; Kantarjian H; Borthakur G
    Cancer; 2011 May; 117(10):2145-55. PubMed ID: 21523727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
    Tiribelli M; Geromin A; Michelutti A; Cavallin M; Pianta A; Fabbro D; Russo D; Damante G; Fanin R; Damiani D
    Cancer; 2011 May; 117(10):2156-62. PubMed ID: 21523728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
    Castaño-Bonilla T; Alonso-Dominguez JM; Barragán E; Rodríguez-Veiga R; Sargas C; Gil C; Chillón C; Vidriales MB; García R; Martínez-López J; Ayala R; Larrayoz MJ; Anguita E; Cuello R; Cantalapiedra A; Carrillo E; Soria-Saldise E; Labrador J; Recio I; Algarra L; Rodríguez-Medina C; Bilbao-Syeiro C; López-López JA; Serrano J; De Cabo E; Sayas MJ; Olave MT; Sánchez-García J; Mateos M; Blas C; López-Lorenzo JL; Lainez-Gonzalez D; Serrano J; Martínez-Cuadrón D; Sanz MA; Montesinos P
    Sci Rep; 2021 Oct; 11(1):20745. PubMed ID: 34671057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J; Wang T; Li S; Lin L; Gang Y
    Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.